secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axogen, Inc. (AXGN)
CIK:        0000805928
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0000805928-23-000146
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axogen Q3 revenue $41.3M (+12% YoY); maintains FY2023 guidance $154-159M
------------------------------------------------------------------------

- Revenue $41.3M (+12% YoY); scheduled non-trauma grew ~20%, emergent trauma mid-single digits.
- Net loss $4.1M ($0.10/sh); adjusted net income $0.7M ($0.01/sh); Adj. EBITDA $2.4M vs $0.4M.
- Gross margin 80.5% (down from 83.3%); FY2023 gross margin expected ~80%.
- Cash & investments $38.6M; new processing facility began tissue processing in Aug.
- Core Accounts 372 (+12% YoY); revenue from Core Accounts now ~65% of total.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/805928/000080592823000146/0000805928-23-000146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/805928/000080592823000146/axgn-20231107.htm
  HTML page:      https://secwatch.observer/filing/0000805928-23-000146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer